NASDAQ:NAYA - Nasdaq - US44984F4019 - Common Stock - Currency: USD
NAYA BIOSCIENCES INC
NASDAQ:NAYA (2/4/2025, 8:00:01 PM)
After market: 0.4999 +0.04 (+8.44%)0.461
+0 (+0.22%)
The current stock price of NAYA is 0.461 USD. In the past month the price decreased by -47.02%.
SARASOTA, Fla. and MIAMI, Jan. 13, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to...
• PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications • NAYA aiming to initiate...
Abstracts demonstrate reversal of resistance to PD1 checkpoint blockade and predictive AI model of HCC survival rate...
SARASOTA, Fla. and MIAMI, Oct. 24, 2024 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to...
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 27.64 | 223.92B | ||
ISRG | INTUITIVE SURGICAL INC | 79.08 | 206.46B | ||
BSX | BOSTON SCIENTIFIC CORP | 43.87 | 152.60B | ||
SYK | STRYKER CORP | 32.19 | 149.59B | ||
MDT | MEDTRONIC PLC | 17.33 | 116.65B | ||
BDX | BECTON DICKINSON AND CO | 18.42 | 70.30B | ||
EW | EDWARDS LIFESCIENCES CORP | 26.72 | 42.07B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 20.6 | 39.72B | ||
IDXX | IDEXX LABORATORIES INC | 41.34 | 38.08B | ||
RMD | RESMED INC | 27.2 | 35.30B | ||
DXCM | DEXCOM INC | 51.45 | 34.16B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 20.23 | 25.29B |
INVO BioScience, Inc. is a fertility company. The company is headquartered in Sarasota, Florida and currently employs 25 full-time employees. The company went IPO on 2008-11-11. The Company’s initial pipeline includes two novel Flex-NK Bispecific Antibodies. NY-303: its GPC3-targeted FLEX-NK Bispecific Antibody for Hepatocellular Carcinoma (HCC). NY-338: its CD38-targeted FLEX-NK Bispecific Antibody for Multiple Myeloma (MM) & Autoimmune Diseases. Its lead GPC3-targeting FLEX-NK bispecific antibody is entering Phase I/II clinical trials and positioned as a monotherapy option to address the unmet needs of the of hepatocellular carcinoma (HCC) patients not responding to standard of care with checkpoint inhibitors. INVOcell is its novel, FDA-cleared and CE-marked intravaginal culture (IVC) device. The company offers a viable alternative to vitro fertilization (IVF) that uses the female body for fertilization and incubation, keeping women at the center of the reproductive process.
NAYA BIOSCIENCES INC
5582 Broadcast Court
Sarasota FLORIDA US
Employees: 25
Company Website: https://www.invobioscience.com/
Investor Relations: http://www.invobioscience.com/investors/
Phone: 19788789505
The current stock price of NAYA is 0.461 USD.
The exchange symbol of NAYA BIOSCIENCES INC is NAYA and it is listed on the Nasdaq exchange.
NAYA stock is listed on the Nasdaq exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for NAYA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of NAYA.
NAYA does not pay a dividend.
NAYA does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.96).
The outstanding short interest for NAYA is 7.08% of its float.
ChartMill assigns a technical rating of 1 / 10 to NAYA.
ChartMill assigns a fundamental rating of 2 / 10 to NAYA. NAYA may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months NAYA reported a non-GAAP Earnings per Share(EPS) of -2.96. The EPS decreased by 76.18% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -43.87% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 43% to NAYA. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of -222.5% and a revenue growth 199.65% for NAYA